Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.61 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945248 | 1.00 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL31293782 | 0.90 | MMP1 (0.58) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL7807672 | 0.88 | ITGA4 (0.50) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL10584324 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL13020623 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL10584328 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL6800679 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL6800676 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL19354815 | 0.86 | CTSS (0.53) | ITGA4ITGB7MAPTTDP1POLB | |
| SCHEMBL8707158 | 0.85 | CTSS (0.61) | MAPTTDP1POLBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| CN-111801100-A | 7-substituted sulfoxy-purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2020-10-20 | — | — | CN | disclosed |
| WO-2019242010-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | 浙江湃肽生物有限公司 | 2019-12-26 | — | — | WO | disclosed |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, UGT1A7 | ITGA4 4246/4885ITGB7 2288/4885MAPT 4063/4885 |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | TPMT, UGT1A7, UGT2B7 | ITGA4 4396/4885ITGB7 2060/4885MAPT 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.